2022 A shares IPO financing amount ranked first in the global stock market.
2022 is coming to an end. The number and amount of IPO in the A-share market are far higher than other major capital markets in the world.
From this year to December 5, the number of IPOs in the A-share market includes public offerings to unspecified qualified investors and listing on Beijing Stock Exchange , with 369 companies below and 546.6 billion yuan in financing. It is estimated that nearly 400 new stocks will be included in 2022, with financing exceeding 560 billion yuan.
With the implementation of more economic stimulus measures and the promotion of macro policies to enhance direct financing of enterprises, it is expected that the number of IPOs in the A-share market in 2023 will reach 400 to 460, and the annual financing amount is expected to hit a new high, reaching 590 billion to 652 billion yuan.
2.
Ma Ben Option Strategy 12.06
Today market differentiated and fluctuated. Yesterday's strong main board was weak, yesterday's weak GEM had a strong volume of 990 billion+, and stock funds continued to rotate in high and low. The
index is strong, but the stocks have already lost money. Today, the high-level stocks have all exploded, and there are many Tianfang (Yongshuntai), which are the limit down. Behind the strength of the
index is the strong stocks of institutions that have a strong holding, Moutai consumer stocks, and Ningde track stocks.
Funds have many stocks trapped in a group, and the rebound has been quite large. When it hits a heavy pressure zone, investors will have to redeem their capital after rebounding, so they will definitely not rebound to unwind the trapped market and let investors redeem them.
Ma Ben Options Short Strategy 500 Contract continues to holdings . Once the rebound is confirmed to be in place and financial consumption is adjusted, will increase its 300 Contract.
3.
China Wuyi 3 limit down !
completely copied the trend at the end of March and early April, when the real estate sector was positive and the last wave of speculation.
As the front leader, China Wuyi has 5 consecutive boards, 6 consecutive boards, 6th board day volume (1.52 billion), with a maximum of 5.69 yuan, and then 3 consecutive limit downs;
China Wuyi is still the front leader, 4 single-line boards, 6 consecutive boards, 6th board 6 (2.41 billion), with a maximum of 5.15 yuan, and then 3 consecutive limit downs;
Real estate leader trend, consistent with the trend of the real estate sector, the previous wave was a down payment and threshold reduction in the interest rate positive stimulus, this wave was a positive stimulus, the two waves of market conditions harvested two waves, and this wave had no courage to liberate the previous wave of trapped markets, and the profit-making market had already been fulfilled.
After all, the emotional market driven by favorable policies is to fight for the first move. Of course, there will never be a shortage of favorable actions and a high-level takeover.
cannot educate, so they have to harvest and eliminate it.
4.
0,000 Tai Bio is favorable to the limit!
million Thai nasal spray influenza virus vector new crown vaccine has been approved for emergency use.
The market interprets this positive situation as a negative one, and it directly opened high and closed low and approached the limit.
trend is similar to Kangtai Bio . new crown vaccine not only did not bring much performance improvement to the company, but set aside a lot of asset impairment.
With the confirmation of the relaxation of the epidemic, the trading logic of the entire biomedical sector has been obviously transferred from the previous new crown medicine industrial chain to pharmaceutical retail, Chinese medicine cold medicine.
logically promotes the new crown , which is equivalent to a cold. Boiled water + cold medicine has become the best solution to the treatment of new crown. Off-site pharmacies stockpile cold medicine, antipyretics, and lotus and clear vermin; hype in the field related targets. The vaccine that benefited in the early stage, testing, consumables, and high-expected new crown drugs and other sectors have been sold out by funds, and the epidemic theme ends.
Looking at the hype in the pharmaceutical sector during the entire epidemic, except for Sinovac making a lot of money, other latecomers basically made a lot of money, while the traditional Chinese medicine Lotus Qingwen Yiling Pharmaceutical is the biggest winner in winning lie down.
5.
Yiling Pharmaceutical has a sky-high price!
Yiling Pharmaceutical today surged and fell back to . The stock price of hit a record high of 48.91 yuan, and the transaction volume of 10.1 billion yuan has been set to a new historical volume.
The epidemic is relaxed, boiled water + cold medicine, it beats the new crown medicine for nucleic acid antigens, and rush to buy Lianhua Qingwen now is a bright card, inside and outside the court, from the main institutions to 10,000 yuan retail investors ignorant and ignorant.
speculation is about expectations. In the context of the positive expectations, it is basically difficult for people to get on the bus even if they have a fish tail. Just use the epidemic to broadcast the favorable consumption directly. The speculation is obviously also extending. What is left for tourism hotels with high expectations before is the long-term performance and digestion of valuations.
Lianhua Qingwen is definitely the ending high point, with a trading volume of 10 billion yuan and a historical high price. It is difficult to have enough funds to pass the flowers in the short term. In the future, the large-level washing-up adjustment will have a different expectation and new hype funds and logic. It is not a bad idea to make another wave.
Whether Lianhua Qingwen’s expectations are full and whether the performance exceeds expectations, let’s see if the epidemic relaxes. At the transaction level of
, tomorrow will be a collection bid for , which is to grab the funds or start the game, which is clear at a glance.
weakly turns stronger, call bidding opens high to grab the counter-package; strong turns weak, call bidding opens low to grab the limit down. Once
becomes stronger and weaker, refer to the front row of , Zhongsheng Pharmaceutical, , and at least 30%-50%.
6. Opportunity direction of pharmaceutical structure
Yesterday, Ma Ben analyzed that as the epidemic relaxed, the hype of the industrial chain related to the biomedical epidemic came to an end. The new medical infrastructure that truly benefits from the high growth in the future will be hyped in October and adjusted in November. Currently, it has the logic and ability to strengthen again.
The relevant targets today's counter-market performance, and the previous wave of leaders is strong, so you can pay attention.
market fills the gap. After the medical adjustment, it is likely to be the main line or structural main line opportunity.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-